Skip to content
Screener

4D Molecular Therapeutics FDMT Cash Flow Statement

Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$72.94M-33.4%-$68.76M-43.3%-$56.88M-29.7%-$54.66M-56.4%
$1.28M+9.8%$1.27M+20.7%$1.22M+10.9%$1.26M+6.0%$1.17M-2.3%
$5.88M+18.7%$4.45M-36.3%$5.55M-26.7%$4.52M-30.4%$4.96M-18.4%
-$70M-61.4%-$68.13M-42.6%-$46.5M-58.2%-$43.38M-43.4%
$55K-90.1%$0-100%$557K+59.6%
$25.54M+284%$68.89M+116%-$128.85M$17.78M-$13.85M+81.2%
$42.34M+4,812%$11.48M$111.98M+18,533%$116K-79.6%$862K-95.0%
$12.25M+177%-$28.6M-1,779%-$56.37M+34.9%
-$70.05M-59.5%-$68.13M-42.2%-$46.41M-48.9%-$43.93M-43.6%

FAQ

How much cash does 4D Molecular Therapeutics generate?
4D Molecular Therapeutics (FDMT) generated -$228.0M in operating cash flow over the trailing twelve months.
What is 4D Molecular Therapeutics's free cash flow?
After $752.0K of capital expenditures, 4D Molecular Therapeutics's free cash flow was -$228.5M over the trailing twelve months, down 46.1% year over year.
Where does 4D Molecular Therapeutics's cash flow data come from?
Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.